Log In
Print
BCIQ
Print
Print this Print this
 

Lenvima, lenvatinib (E7080)

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionSelective inhibitor of vascular endothelial growth factor (VEGF) receptors, fibroblast growth factor (FGF) receptors (FGFR), stem cell factor (SCF) receptor tyrosine kinase (c-Kit; KIT; CD117), platelet derived growth factor receptor (PDGFR) and RET
Molecular Target Vascular endothelial growth factor (VEGF) receptor ; Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) kinase inhibitor; Vascular endothelial growth factor (VEGF) receptor 1 (Flt-1) kinase inhibitor; Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) inhibitor; Fibroblast growth factor (FGF) receptor 1 (FGFR1) inhibitor; Fibroblast growth factor (FGF) receptor 2 (FGFR2) inhibitor; Fibroblast growth factor (FGF) receptor 3 (FGFR3) inhibitor; Platelet derived growth factor receptor A (PDGFRA) inhibitor; Vascular endothelial growth factor (VEGF) receptor 3 (FLT4) (VEGFR-3) inhibitor; Fibroblast growth factor (FGF) receptor 4 (FGFR4) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today